Integra LifeSciences entered into an agreement with AlloSource.
Here are four takeaways:
1. AlloSource is a provider of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care.
2. Under the agreement, Integra gains access to acellular dermal matrices derived from donated human dermis along with rights to market these matrices.
3. In particular, Integra's new product line, marketed under the name HuMend Acellular Dermal Matrix, will allow Integra to offer soft tissue repair solutions for patients undergoing plastic reconstructive procedures.
4. Integra expects to launch HuMend in mid-2016.